Open AccessHepatocyte Growth Factor Is Required for Mesenchymal Stromal Cell Protection Against Bleomycin‐Induced Pulmonary Fibrosis
Author(s) -
Cahill Emer F.,
Kennelly Helen,
Carty Fiona,
Mahon Bernard P.,
English Karen
Publication year - 2016
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2015-0337
Subject(s) - hepatocyte growth factor , bleomycin , mesenchymal stem cell , pulmonary fibrosis , cancer research , proinflammatory cytokine , fibrosis , idiopathic pulmonary fibrosis , stromal cell , apoptosis , medicine , immunology , biology , inflammation , pathology , lung , biochemistry , receptor , chemotherapy
In vitro studies elucidate an important role for the mesenchymal stromal cell (MSC)‐derived soluble factors hepatocyte growth factor (HGF) and prostaglandin E 2 in promoting wound healing and inhibiting apoptosis. This study translates these findings, thereby demonstrating that HGF is involved in the protective effects mediated by MSC in vivo in the bleomycin model. These findings support a targeted approach to enhancing MSC therapy for fibrotic disease and address the importance of the timing of MSC therapy.